Reported Sunday, Lantheus Unveils Phase 3 SPLASH Trial Results In PSMA-Positive Metastatic Prostate Cancer At ESMO 2024
Portfolio Pulse from Benzinga Newsdesk
Lantheus presented positive Phase 3 SPLASH trial results for PSMA-positive metastatic prostate cancer at ESMO 2024. The study met its primary endpoint, showing significant improvement in radiographic progression-free survival and overall response rate. Patients also showed improved health-related quality of life.
September 16, 2024 | 7:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantheus' Phase 3 SPLASH trial results for PSMA-positive metastatic prostate cancer showed significant improvements in survival and quality of life, potentially boosting investor confidence and stock price.
The positive Phase 3 trial results are likely to boost investor confidence in Lantheus, as they demonstrate significant improvements in key clinical outcomes for prostate cancer treatment. This could lead to an increase in stock price as the market reacts to the potential for future revenue growth from successful drug development.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100